# Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome

> **NCT05704400** · PHASE2 · UNKNOWN · sponsor: **Istituto Giannina Gaslini** · enrollment: 20 (estimated)

## Conditions studied

- Nephrotic Syndrome

## Interventions

- **DRUG:** Rituximab Biosimilar ABP 798
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT05704400
- **Lead sponsor:** Istituto Giannina Gaslini
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-01
- **Primary completion:** 2024-03-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05704400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05704400, "Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05704400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*